10-Q Filing

INSIGHT MOLECULAR DIAGNOSTICS INC. CIK: 1642380 Q1 2021

Filing Information

Form Type	10-Q
Accession Number	`0001493152-21-011836`
Period End Date	20210331
Filing Date	20210517
Fiscal Year	2021
Fiscal Period	Q1
XBRL Instance	ocx-20210331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 71 Income Statement 38 Cash Flow Statement 88 Comprehensive Income 6

Balance Sheet 71 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock, no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$58.91M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.14M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$703.00K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$203.00K	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$675.00K	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$887.00K	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	150.00M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$2.33M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	150.00M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.21M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	69.12M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$62.82M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$9.23M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	88.91M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	69.12M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	88.91M	shares	Point-in-time
Right-of-use assets, machinery and equipment, net, and construction in progress	`RightofuseAssetsMachineryAndEquipmentNet`	$6.52M	USD	Point-in-time
Right-of-use assets, machinery and equipment, net, and construction in progress	`RightofuseAssetsMachineryAndEquipmentNet`	$7.27M	USD	Point-in-time
Equity method investment in Razor	`EquityMethodInvestments`	$13.42M	USD	Point-in-time
Equity method investment in Razor	`EquityMethodInvestments`	-	USD	Point-in-time
Goodwill	`Goodwill`	$9.19M	USD	Point-in-time
Goodwill	`Goodwill`	$9.19M	USD	Point-in-time
Goodwill	`Goodwill`	$9.19M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$47.99M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$15.01M	USD	Point-in-time
Deposits and other noncurrent assets	`DepositsAndOtherNoncurrentAssets`	$2.04M	USD	Point-in-time
Deposits and other noncurrent assets	`DepositsAndOtherNoncurrentAssets`	$2.06M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$129.31M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$55.42M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$432.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.09M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$5.75M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$5.26M	USD	Point-in-time
Loans payable, current	`LoansPayableCurrent`	$2.39M	USD	Point-in-time
Loans payable, current	`LoansPayableCurrent`	$2.59M	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$740.00K	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$422.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$9.69M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$9.00M	USD	Point-in-time
Loans payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	$1.51M	USD	Point-in-time
Loans payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	$951.00K	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$4.31M	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$3.86M	USD	Point-in-time
Contingent consideration liabilities	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$8.18M	USD	Point-in-time
Contingent consideration liabilities	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$7.12M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$21.94M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$22.68M	USD	Point-in-time
Commitments and contingencies (Note 14)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 14)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, no par value, 150,000 shares authorized; 88,914 and 69,117 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	`CommonStockValue`	$157.16M	USD	Point-in-time
Common stock, no par value, 150,000 shares authorized; 88,914 and 69,117 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	`CommonStockValue`	$234.22M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-123.68M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-127.60M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$30.84M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$33.48M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$106.63M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$36.62M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$55.42M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$129.31M	USD	Point-in-time

Income Statement 38 line items

Line Item	Tag	Value	Unit	Period
Total revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$16.00K	USD	1 Quarter
Total revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.12M	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$158.00K	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$738.00K	USD	1 Quarter
Cost of revenues - amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	$15.00K	USD	1 Quarter
Cost of revenues - amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	$307.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$2.16M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$3.36M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$4.76M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$4.62M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$2.25M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$1.49M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$1.06M	USD	1 Quarter
Total costs and operating expenses	`CostsAndOperatingExpenses`	$8.45M	USD	1 Quarter
Total costs and operating expenses	`CostsAndOperatingExpenses`	$12.48M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-11.36M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-8.43M	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNet`	$-22.00K	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNet`	$-68.00K	USD	1 Quarter
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-53.00K	USD	1 Quarter
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$213.00K	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-329.00K	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-270.00K	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$8.00K	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$2.00K	USD	1 Quarter
Total other expenses, net	`NonoperatingIncomeExpense`	$-123.00K	USD	1 Quarter
Total other expenses, net	`NonoperatingIncomeExpense`	$-396.00K	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-8.83M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-11.48M	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$-1.09M	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$-7.56M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-7.73M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-3.92M	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.13	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.05	USD	1 Quarter
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	82.12M	shares	1 Quarter
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	61.46M	shares	1 Quarter

Cash Flow Statement 88 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-7.73M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.92M	USD	1 Quarter
Depreciation expense	`Depreciation`	$60.00K	USD	1 Quarter
Depreciation expense	`Depreciation`	$121.00K	USD	1 Quarter
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$307.00K	USD	1 Quarter
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$15.00K	USD	1 Quarter
Amortization of right-of-use assets and liabilities	`AmortizationOfRightOfUseAssetsAndLiabilities`	$25.00K	USD	1 Quarter
Amortization of right-of-use assets and liabilities	`AmortizationOfRightOfUseAssetsAndLiabilities`	$152.00K	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-329.00K	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-270.00K	USD	1 Quarter
Amortization of prepaid maintenance	`AmortizationOfPrepaidMaintenance`	$21.00K	USD	1 Quarter
Amortization of prepaid maintenance	`AmortizationOfPrepaidMaintenance`	$36.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$937.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$1.29M	USD	1 Quarter
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-53.00K	USD	1 Quarter
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$213.00K	USD	1 Quarter
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$19.00K	USD	1 Quarter
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$35.00K	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$1.06M	USD	1 Quarter
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-1.09M	USD	1 Quarter
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-7.56M	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$499.00K	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-8.00K	USD	1 Quarter
Amount due to Lineage and affiliates	`IncreaseDecreaseInDueToRelatedParties`	-	USD	1 Quarter
Amount due to Lineage and affiliates	`IncreaseDecreaseInDueToRelatedParties`	$-6.00K	USD	1 Quarter
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$909.00K	USD	1 Quarter
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$1.17M	USD	1 Quarter
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$405.00K	USD	1 Quarter
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$1.25M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-9.85M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-6.87M	USD	1 Quarter
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$6.19M	USD	1 Quarter
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$607.00K	USD	1 Quarter
Acquisition of Razor Genomics asset, net of cash acquired	`AcquisitionOfRazorGenomicsAssetNetOfCashAcquired`	$6.65M	USD	1 Quarter
Acquisition of Razor Genomics asset, net of cash acquired	`AcquisitionOfRazorGenomicsAssetNetOfCashAcquired`	-	USD	1 Quarter
Deposit paid for Chronix merger agreement	`PaymentForDeposits`	$175.00K	USD	1 Quarter
Deposit paid for Chronix merger agreement	`PaymentForDeposits`	-	USD	1 Quarter
Construction in progress and purchases of furniture and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$44.00K	USD	1 Quarter
Construction in progress and purchases of furniture and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$842.00K	USD	1 Quarter
Security deposit and other	`ProceedsFromSecurityDepositAndOther`	$10.00K	USD	1 Quarter
Security deposit and other	`ProceedsFromSecurityDepositAndOther`	$42.00K	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-8.26M	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-6.19M	USD	1 Quarter
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$348.00K	USD	1 Quarter
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	-	USD	1 Quarter
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$65.26M	USD	1 Quarter
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$7.60M	USD	1 Quarter
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$2.68M	USD	1 Quarter
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$1.00K	USD	1 Quarter
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromIssuanceOfPrivatePlacement`	$6.75M	USD	1 Quarter
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromIssuanceOfPrivatePlacement`	-	USD	1 Quarter
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	-	USD	1 Quarter
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	$203.00K	USD	1 Quarter
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	1 Quarter
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$802.00K	USD	1 Quarter
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	$14.00K	USD	1 Quarter
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	-	USD	1 Quarter
Repayment of loan payable	`RepaymentsOfDebt`	$375.00K	USD	1 Quarter
Repayment of loan payable	`RepaymentsOfDebt`	-	USD	1 Quarter
Repayment of financing lease obligations	`FinanceLeasePrincipalPayments`	$41.00K	USD	1 Quarter
Repayment of financing lease obligations	`FinanceLeasePrincipalPayments`	$17.00K	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$7.57M	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$69.87M	USD	1 Quarter
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$51.76M	USD	1 Quarter
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-5.50M	USD	1 Quarter
At beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
At beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.77M	USD	Point-in-time
At beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$18.28M	USD	Point-in-time
At beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$60.61M	USD	Point-in-time
At end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
At end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.77M	USD	Point-in-time
At end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$18.28M	USD	Point-in-time
At end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$60.61M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	$44.00K	USD	1 Quarter
Cash paid for interest	`InterestPaidNet`	$43.00K	USD	1 Quarter
Common stock issued for acquisition of Razor Genomics asset	`StockIssued1`	$5.76M	USD	1 Quarter
Common stock issued for acquisition of Razor Genomics asset	`StockIssued1`	-	USD	1 Quarter
Deferred tax liability generated from the acquisition of Razor Genomics asset	`DeferredTaxLiabilityGeneratedFromAcquisitionOfRazorGenomicsAsset`	-	USD	1 Quarter
Deferred tax liability generated from the acquisition of Razor Genomics asset	`DeferredTaxLiabilityGeneratedFromAcquisitionOfRazorGenomicsAsset`	$7.56M	USD	1 Quarter
Common stock issued for acquisition of Insight Genetics	`CommonStockIssuedForAcquisition`	-	USD	1 Quarter
Common stock issued for acquisition of Insight Genetics	`CommonStockIssuedForAcquisition`	$5.00M	USD	1 Quarter
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`CapitalExpendituresIncurredButNotYetPaid`	$139.00K	USD	1 Quarter
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`CapitalExpendituresIncurredButNotYetPaid`	-	USD	1 Quarter
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	-	USD	1 Quarter
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	$11.13M	USD	1 Quarter
Holdback liability	`HoldbackLiability`	-	USD	1 Quarter
Holdback liability	`HoldbackLiability`	$600.00K	USD	1 Quarter

Comprehensive Income 6 line items

Line Item	Tag	Value	Unit	Period
NET LOSS	`NetIncomeLoss`	$-7.73M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-3.92M	USD	1 Quarter
Other comprehensive loss, net of tax	`OtherComprehensiveIncomeLossNetOfTax`	-	USD	1 Quarter
Other comprehensive loss, net of tax	`OtherComprehensiveIncomeLossNetOfTax`	-	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-3.92M	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-7.73M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.